Kolkata hospital part of Covid drug trial – ET HealthWorld


Kolkata: The Swiss-made Tocilizumab, which is in high demand for treatment of severely infected Covid-19 patients, will be pitted against an Indian drug of the same formulation to study if the latter matches up to the efficacy of the original product.

Peerless Hospital will be among 10 Indian hospitals where Tocilizumab’s Indian version will undergo ‘therapeutic equivalent trial’.


Tocilizumab is used for inhibiting cytokine storm which many Covid-19 infected patients undergo. If the uncontrolled cytokine production is not countered, it could affect various organs of the patient.

“The human body produces cytokine as defence whenever there is any infection/inflammation. But the trouble is when the cytokine production gets uncontrolled. Tocilizumab is used to fight this cytokine storm,” said Ajoy Sarkar, clinical director, critical care unit at Peerless. Sarkar will be the principal investigator.


Currently, the drug is being imported and due to the high demand and its scarcity, there have been instances of black marketing during the second wave. Priced at Rs 40,000 a vial, patients need to be given the injection before they land up on ventilation. Due to the shortage, its supply is being rationed and centralised from the state health department.

“The window period during which a patient has to be administered the drug is crucial for better outcome. If the Indian version being produced by Hetero Pharma proves its efficacy and is approved, the supply chain will improve. Besides, it’s cheaper,” said Sarkar.


During the trial, a section of patients will be given Swiss-made drug while another set will get the Hetero Pharma’s product. The outcome will be complied and compared. Patients who will be part of the trial will get the drug free of cost.

The DCGI as well as the hospital’s ethics committee have already given green signal to the trial which is expected to begin in about a week.

instant= new adsenseLoader( '#quads-ad4-place', { onLoad: function( ad ){ if (ad.classList.contains("quads-ll")) { ad.classList.remove("quads-ll"); } } });

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook


We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health News Click Here 


 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a comment